The interrelationship of depression and diabetes

doi:10.1017/CBO9780511544293.009

8 - The interrelationship of depression and diabetes

from Part 2 - Depression and specific health problems

Published online by Cambridge University Press: 17 September 2009

Dominique L. Musselman ,

Ephi Betan and

Edited by

Dominique L. Musselman: Affiliation:
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
Angela Bowling: Affiliation:
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
Natalie Gilles: Affiliation:
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
Hannah Larsen: Affiliation:
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA
Ephi Betan: Affiliation:
Georgia School of Professional Psychology, Atlanta, GA, USA
Lawrence S. Phillips: Affiliation:
Department of Medicine, Division of Endocrinology, Emory University School of Medicine, Atlanta, GA, USA
Andrew Steptoe: Affiliation:
University College London

Book contents

Get access

Summary

… in the pre-war literature, diminished glucose tolerance was frequently reported to be statistically demonstrable in patients with melancholia.

H. M. Von Praag (1965)

Introduction: diabetes

The worldwide prevalence of diabetes is increasing at an alarming rate. According to the World Health Organization (WHO), approximately 150 million people worldwide have diabetes mellitus. Due to the combined impact of sedentary lifestyles, increased prevalence of obesity, and the rising age of the population, this number may double by 2025. In developed countries, people aged 65 or older will be at highest risk; however, most new cases in developing countries will be individuals between 45 and 64 years of age. Countries reporting the largest number of cases are India, followed (in order) by China, the USA, Indonesia, Japan, Pakistan, Russia, Brazil, Italy and Bangladesh [1]

Diabetes mellitus is a heterogeneous metabolic disease in which hyperglycaemia is a central feature. Diabetes is the world's leading cause of non-traumatic limb amputation, new cases of end-stage renal disease [2] and blindness in adults [1, 3]. Nearly 50% of the 18 million diabetes patients in the USA are unaware of their diabetes [4]; in some countries, that number may be as high as 80% [5]. Other debilitating consequences of diabetes include diabetic neuropathy and foot ulcers. Diabetes is the fourteenth leading cause of death worldwide and also contributes to cardiac and stroke-related morbidity and mortality.

Keywords

antidepressant agents cognitive-behavioural therapy depression diabetes mellitus psychological pathways WHO glycaemic control glucose concentration

Type: Chapter
Information: Depression and Physical Illness , pp. 165 - 194

DOI: https://doi.org/10.1017/CBO9780511544293.009 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

World Health Organization. Diabetes: The Cost of Diabetes (Geneva: World Health Organization, 2002).

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993), 977–86.

Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D., DeMets, D. L., The Wisconsin Epidemiologic Study of Diabetes Retinopathy III: prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. Opthalmol. 102 (1984), 527–32.Google Scholar

Associated Press. Estimate of Americans with pre-diabetes doubles. Wall Street Journal, April 29, 2004.

World Health Organization. Laboratory Diagnosis and Monitoring of Diabetes Mellitus (Geneva: World Health Organization, 2002).

Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. Guidelines for the management of mild hypertension. Hypertension 22 (1993), 392–403.

McDaniel, J. S., Musselman, D. L., Porter, M. R., Reed, D. A., Nemeroff, C. B., Depression in the cancer patient: a commentary on diagnosis, biology, and treatment. Arch. Gen. Psychiatry 52 (1995), 89–99.Google Scholar

C. Bradley, The well-being questionnaire. In Handbook of Psychology and Diabetes, ed. Bradley, C. (chur, Switzerland: Harwood Academic Publishers, 1994), pp. 89–109.

Lustman, P. J., Amado, H., Wetzel, R. D., Depression in diabetics: a critical appraisal. Comp. Psychiatry 1 (1983), 65–74.Google Scholar

Beck, A. T., Ward, C. H., Mendelson, M., Mock, J., Erbaugh, J., An inventory for measuring depression. Arch. Gen. Psychiatry 4 (1961), 561–71.Google Scholar

Lustman, P. J., Griffith, L. S., Gavard, J. A., Clouse, R. E., Depression in adults with diabetes. Diabetes Care 15 (1992), 1631–9.Google Scholar

Lustman, P. J., Freedland, K. E., Carney, R. M., Hong, B. A., Clouse, R. E., Similarity of depression in diabetic and psychiatric patients. Psychosom. Med. 54 (1992), 602–11.Google Scholar

Lustman, P. J, Griffith, L. S., Clouse, R. E., et al., Effects of nortriptyline on depression and glucose regulation in diabetes: results of a double-blind, placebo-controlled trial. Psychosom. Med. 59 (1997), 241–50.Google Scholar

Ciechanowski, P., Katon, W., Russo, J., The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Diabetes Care 25 (2002), 731–6.Google Scholar

Edge, L. E., Zheng, D., Simpson, K., Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care 25 (2002), 464–70.Google Scholar

Gavard, J. A., Lustman, P. J., Clouse, R. E., Prevalence of depression in adults with diabetes: an epidemiological evaluation. Diabetes Care 16 (1993), 1167–78.Google Scholar

Anderson, R. J., Freedland, K. E., Clouse, R. E., Lustman, P. J., The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24 (2001), 1069–78.Google Scholar

Gary, T. L., Crum, R. M., Cooper-Patrick, L., Ford, D., Brancati, F. L., Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care 23 (2000), 23–9.Google Scholar

Black, S. A., Goodwin, J. S., Markides, K. S., The association between chronic diseases and depressive symptomatology in older Mexican Americans. J. Gerontol. A Biol. Sci. Med. Sci. 53A (1998), M188–94.Google Scholar

Grandinetti, A., Kaholokula, J. K., Crabbe, K. M., et al., Relationship between depressive symptoms and diabetes among native Hawaiians. Psychoneuroendocrinology 25 (2000), 239–46.Google Scholar

Warnock, J. K., Mutzig, E. M., Diabetes mellitus and major depression: considerations for treatment of Native Americans. J. Okla. State Med. Assoc. 91 (1998), 488–93.Google Scholar

Ostler, K., Thompson, C., Kinmonth, A. L., et al., Influence of socio-economic deprivation on the prevalence and outcome of depression in primary care: the Hampshire Depression project. Br. J. Psychiatry 178 (2001), 12–17.Google Scholar

Everson, S. A., Saty, S. C., Lynch, J. W., Kaplan, G. A., Epidemiologic evidence for the relation between socioeconomic status and depression, obesity, and diabetes. J. Psychosom. Res. 53 (2002), 891–5.Google Scholar

Lynch, J. W., Kaplan, G. A., Shema, S. J., Cumulative impact of sustained economic hardship on physical, cognitive, psychological, and social functioning. N. Engl. J. Med. 337 (1997), 1889–95.Google Scholar

Ross, C. E., Neighborhood disadvantage and adult depression. J. Health Soc. Behav. 41 (2000), 177–87.Google Scholar

Saul, C., Payne, N., How does the prevalence of specific morbidities compare with measures of socio-economic status at small area level?J. Public Health Med. 21 (1999), 340–47.Google Scholar

Fisher, L., Chesla, C. A., Mullan, J. T., Skaff, M. M., Kanter, R. A., Contributors to depression in Latino and European-American patients with type 2 diabetes. Diabetes Care 24 (2001), 1751–7.Google Scholar

Peyrot, M., Rubin, R. R., Levels and risk of depression and anxiety symptomatology among diabetic adults. Diabetes Care 20 (1997), 585–90.Google Scholar

Lustman, P. J., Griffith, L. S., Clouse, R. E., Cryer, P. E., Psychiatric illness in diabetes: relationship to symptoms and glucose control. J. Nerv. Ment. Dis. 174 (1986), 736–42.Google Scholar

Lloyd, C. E., Matthews, K. A., Wing, R. R., Orchard, T. J., Psychosocial factors and complications of IDDM: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 15 (1992), 166–72.Google Scholar

Lustman, P. J., Griffith, L. S., Clouse, R. E., Depression in adults with diabetes: results of 5-year follow-up study. Diabetes Care 11 (1988), 605–12.Google Scholar

Lustman, P. J., Anderson, R. J., Freedland, K. E., et al., Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23 (2000), 934–42.Google Scholar

Ziemer, D. C., Ferguson, S. F., Kieltyka, R. L., Slocum, W., Barriers to appointment keeping in a municipal hospital diabetes clinic. Diabetes 47, Suppl 1 (1998), A144.Google Scholar

Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E., Lustman, P. J., Association of depression and diabetes complications: a meta-analysis. Psychosom. Med. 63 (2001), 619–30.Google Scholar

Vinnamaki, H., Niskanen, L., Uusitupa, M., Mental well-being in people with non-insulin dependent diabetes. Acta Psychiatr. Scand. 92 (1995), 392–7.Google Scholar

Mazze, R. S., Lucido, D., Shamoon, H., Psychological and social correlates of glycemic control. Diabetes Care 7 (1984), 360–66.Google Scholar

Testa, M. A., Simonson, D. C., Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. J. Am. Med. Assoc. 280 (1998), 1490–96.Google Scholar

Hayward, C., Psychiatric illness and cardiovascular disease risk. Epidemiol. Rev. 17 (1995), 129–38.Google Scholar

Eaton, W. W., Armenian, H., Gallo, J., Pratt, L., Ford, E., Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care 22 (1996), 1097–102.Google Scholar

Robins, L. N., Helzer, J. E., Croughan, J. L., Williams, J. B. W., Spitzer, R. L., The NIMH Diagnostic Interview Schedule, Version III (Washington, DC: Public Health Service [HSS], 1981).

Zung, W. W., A self-rating depression scale. Arch. Gen. Psychiatry 12 (1965), 63–70.Google Scholar

Everson-Rose, S. A., Meyer, P. M., Powell, L. H., et al., Depressive symptoms, insulin resistance, and risk of diabetes in women in midlife. Diabetes Care 27 (2004), 2856–62.Google Scholar

Radloff, L. S., The CES-D scale: a self-report depression scale for research in the general population. J. Appl. Psychol. Meas. 1 (1977), 385–401.Google Scholar

Kawakami, N., Tkatsuka, N., Shimizu, H., Ishibashi, H., Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 22 (1999), 1071–6.Google Scholar

Ciechanowski, P. S., Katon, W. J., Russo, J. E., Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med. 1160 (2000), 3278–85.Google Scholar

Katon, W. J., Korff, M., Lin, E., et al., Population-based care of depression: effective disease management strategies to decrease prevalence. Gen. Hosp. Psychiatry 19 (1997), 169–78.Google Scholar

Egede, L. E., Zheng, D., Simpson, K., Comorbid depression is associated with increased health care use and expenditure in individuals with diabetes. Diabetes Care 25 (2002), 464–70.Google Scholar

Clouse, R. E., Lustman, P. J., Freedland, K. E., et al., Depression and coronary heart disease in women with diabetes. Psychosom. Med. 65 (2003), 376–83.Google Scholar

Frasure-Smith, N., Lesperance, F., Juneau, M., Talajic, M., Bourassa, M. G., Gender, depression, and one-year prognosis after myocardial infarction. Psychosom. Med. 61 (1999), 26–37.Google Scholar

Sapolsky, R. M., Romero, L. M., Munck, A. U., How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulator and preparative actions. Endocrinol. Rev. 21 (2000), 55–89.Google Scholar

D. L. Musselman, C. DeBatista, K. I. Nathan, et al., Biology of mood disorders. In Textbook of Psychopharmacology, 2nd edn, ed. Schatzberg, A. F., Nemeroff, C. B. (Washington, DC: American Psychiatric Press, 1998), pp. 550–88.

A. Munck, A. Naray-Fejes-Toth, Glucocorticoid action: physiology. In Endocrinology, ed. Groot, L. J. (Philadelphia: W. B. Saunders, 1995), pp. 1642–56.

Eigler, N., Sacca, L., Sherwin, R. S., Synergistic interactions of physiologic increments of glucagon, epinephrine and cortisol in the dog: a model for stress-induced hyperglycemia. J. Clin. Invest. 63 (1979), 114–23.Google Scholar

DeFronzo, R., Sherwin, R. S., Felig, P., Synergistic interactions of counterregulatory hormones: a mechanism for stress hyperglycemia. Acta Chir. Scand. Suppl. 498 (1980), 33–9.Google Scholar

Brindley, D. N., Rolland, Y., Possible connections between stress, diabetes, obesity, hypertension and altered lipoprotein metabolism that may result in atherosclerosis. Clin. Sci. (Land.) 77 (1989), 453–61.Google Scholar

Dallman, M. F., Strack, A. M., Akana, S. F., et al., Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front. Neuroendocrinol. 14 (1993), 303–47.Google Scholar

Weinstein, S. P., Paquin, T., Pritsker, A., Haber, R. A., Glucocorticoid-induced insulin resistance: dexamethsone inhibits the activation of glucose transport in rat skeletal muscle by both insulin- and non-insulin-related stimuli. Diabetes 44 (1995), 441–5.Google Scholar

Mueller, P. S., Heninger, G. R., McDonald, R. K., Intravenous glucose tolerance test in depression. Arch. Gen. Psychiatry 21 (1968), 470–77.Google Scholar

Wright, J. H., Jacisin, J. J., Radin, N. S., Glucose metabolism in unipolar depression. Br. J. Psychiatry 132 (1978), 386–93.Google Scholar

Winokur, A., Maislin, G., Phillips, J. L., Amsterdam, J. D., Insulin resistance after oral glucose tolerance testing in patients with major depression. Am. J. Psychiatry 145 (1988), 325–30.Google Scholar

Sachar, E. J., Finkelstein, J., Hellman, L., Growth hormone responses in depressive illness: 1. Response to insulin tolerance test. Arch. Gen. Psychiatry 25 (1971), 263–9.Google Scholar

Casper, R. C., Davis, J. M., Pandey, G., Garver, D., Dekirmenjian, H., Neuroendocrine and amine studies in affective illness. Psychoneuroendocrinology 2 (1977), 105–13.Google Scholar

Duelli, R., Kuschinsky, W., Brain glucose transporters: relationship to local energy demand. N. Physiol. Sci. 16 (2001), 71–6.Google Scholar

Baxter, L. R., Phelps, M. E., Mazziotta, J. C., et al., Cerebral metabolic rates for glucose in mood disorders studied with positron emission tomography (PET) and (F-18)-fluro-2-deoxyglucose (FDG). Arch. Gen. Psychiatry 42 (1985), 441–7.Google Scholar

Baxter, L. R., Schwartz, J. M., Phelps, M. E., et al., Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 46 (1989), 243–50.Google Scholar

Martinot, J. L., Hardy, P., Feline, A., et al., Left prefrontal glucose metabolism in the depressed state: a confirmation. Am. J. Psychiatry 147 (1990), 1313–17.Google Scholar

Simpson, I. A., Chundru, K. R., Davies-Hill, T., Honer, W. G., Davies, P., Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35 (1994), 511–12.Google Scholar

Gamberino, W. C., Brennan, W. A. Jr, Glucose transporter isoform expression in Huntington's disease brain. J. Neurochem. 63 (1994), 1392–7.Google Scholar

Kuhl, D. E., Phelps, M. E., Markham, C. H., et al., Cerebral metabolism and atrophy in Huntington's disease. Ann. Neurol. 12 (1982), 425–34.Google Scholar

Rothman, D. L., Magnusson, I., Cline, G., et al., Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 983–7.Google Scholar

Petersen, K. F., Shulman, G. I., Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 90 (2002), 11–18G.Google Scholar

Shulman, G. I., Rothman, D. L., Jue, T., et al., Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin dependent diabetes mellitus by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322 (1990), 223–8.Google Scholar

Ross, R., Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999), 115–26.Google Scholar

Fried, S. K., Bunkin, D. A., Greenburg, A. S., Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 83 (1998), 847–50.Google Scholar

Fernandez-Real, J. M., Vayred, M., Richart, C., et al., Circulating interleukin 6 levels, blood pressure, and insulin insensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab. 86 (2001), 1154–9.Google Scholar

Paolisso, G., Rizzo, M. R., Mazziotti, G., et al., Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am. J. Physiol. 275 (1998), E294–9.Google Scholar

Hotamisligil, G. S., Shargill, N. S., Spiegelman, B. M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993), 87–91.Google Scholar

Hotamisligil, G. S., Budavari, A., Murray, D., Spiegelman, B. M., Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J. Clin. Invest. 94 (1994), 1543–9.Google Scholar

Hotamisligil, G. S., Spiegelman, B. M., Tumor necrosis factor a: a key component of the obesity-diabetes link. Diabetes 43 (1994), 1271–8.Google Scholar

Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., Spiegelman, B. M., Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance. J. Clin. Invest. 95 (1995), 2409–15.Google Scholar

Kern, P. A., Szaghizadah, M., Ong, J. M., et al., The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95 (1995), 2111–19.Google Scholar

Hotamisligil, G. S., Peraldi, P., Budavari, A., et al., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996), 665–8.Google Scholar

Saghizadeh, M., Ong, J. M., Garvey, W. T., Henry, R. R., Kern, P. A., The expression of TNFa by human muscle: relationship to insulin resistance. J. Clin. Invest. 97 (1996), 1111–16.Google Scholar

Kent, S., Bluthe, R. M., Kelley, K. W., Dantzer, R., Sickness behavior as a new target for drug development. Trends Pharmacol. Sci. 13 (1992), 24–8.Google Scholar

Yirmiya, R., Endotoxin produces a depressive-like episode in rats. Brain Res. 711 (1996), 163–74.Google Scholar

Maes, M., Scharpe, S., Meltzer, H. Y., et al., Increased neopterin and interferon-gamma secretion and lower availability of l-tryptophan in major depression: further evidence for an immune response. Psychiatr. Res. 54 (1994), 143–60.Google Scholar

Maes, M., Vendoolaeghe, E., Ranjan, R., et al., Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J. Affect. Dis. 36 (1995), 2–36.Google Scholar

Maes, M., Smith, R., Christophe, A., et al., Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omega-6/C20:5 omega-3 ratio in cholesteryl esters and phospholipids. J. Affect. Dis. 38 (1996), 35–46.Google Scholar

Berk, M., Wadee, A. A., Kuschke, R. H., O'Neill-Kerr, A., Acute-phase proteins in major depression. J. Psychosom. Res. 43 (1997), 529–34.Google Scholar

Frommberger, U. H., Bauer, J., Haselbauer, P., et al., Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 247 (1997), 228–33.Google Scholar

Miller, G. E., Stetler, C. A., Carney, R. M., Freedland, K. E., Banks, W. A., Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Cardiol. 90 (2002), 1279–83.Google Scholar

Musselman, D. L., Miller, A. H., Porter, M. R., et al., Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 158 (2001), 1252–7.Google Scholar

Snoek, F. J., Skinner, T. C., Psychological counselling in problematic diabetes: does it help?Diabetes Med. 19 (2002), 265–73.Google Scholar

Lustman, P. J., Griffith, L. S., Freedland, K. E., Kissel, S. S., Clouse, R. E., Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized, controlled trial. Ann. Intern. Med. 129 (1998), 613–21.Google Scholar

Thaler, L. M., Ziemer, D. C., Gallina, D. L., et al., Availability of rapid HbA1c measurements enhances clinical decision-making. Diabetes Care 22 (1999), 1415–21.Google Scholar

Lustman, P. J., Harper, G. W., Nonpsychiatric physicians' identification and treatment of depression in patients with diabetes. Comp. Psychiatry 28 (1987), 22–7.Google Scholar

Cook, C. B., Phillips, L. S., El-Kebbi, I. M., et al., Diabetes in urban African-Americans: XVII. Improved diabetes management over five years with nurse provider-led care at a large municipal hospital. Diabetes Care 22 (1999), 1494–500.Google Scholar

Miller, C. D., Phillips, L. S., Ziemer, D. C., et al., Hypoglycemia in patients with type 2 diabetes. Arch. Intern. Med. 161 (2001), 1653–9.Google Scholar

Slocum, W., Ziemer, D. C., Culler, S. D., Cook, C., Ferguson, S. Y., Poor appointment keeping behavior worsens glycemic control. Diabetes 48: Suppl 1 (1999), A197.Google Scholar

Goodnick, P. J., Henry, J. H., Buki, V. M. V., Treatment of depression in patients with diabetes mellitus. J. Clin. Psychiatry 56 (1995), 128–36.Google Scholar

Praag, H. M., Leijnse, B., Depression, glucose tolerance, peripheral glucose uptake and their alterations under the influence of anti-depressive drugs of the hydrazine type. Psychopharmacologia 8 (1965), 67–78.Google Scholar

Max, M. B., Kishore-Kumar, R., Schafer, S. C., et al., Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 45 (1991), 3–9.Google Scholar

Max, M. B., Lynch, S. A., Muir, J., et al., Effects of desipramine, amitriptyline, and fluoxetine in diabetic neuropathy. N. Engl. J. Med. 326 (1992), 1250–56.Google Scholar

Rabkin, J., Quitkin, F., Harrison, W., McGrath, P., Tricamo, E., Adverse reactions to monoamine oxidase inhibitors: I. A comparative study. J. Clin. Psychopharmacol. 4 (1984), 270–78.Google Scholar

P. R. Muskin, A. H. Glassman, The use of tricyclic antidepressants in a medical setting. In Consultation-liaison Psychiatry: Current Trends and Future Perspectives, ed. Finkel, J. B. (New York: Grune & Stratton, 1983), pp. 137–58.

Roose, S. P., Dalack, G. W., Treating the depressed patient with cardiovascular problems. J. Clin. Psychiatry 53 (1992), 25–31.Google Scholar

Sindrup, S. H., Gram, L. F., Brosen, K., Eshoj, O., Mogensen, E. F., The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42 (1990), 135–44.Google Scholar

DeVane, C. L., Markowitz, J. S., Psychoactive drug interactions with pharmacotherapy for diabetes. Psychopharmacol. Bull. 36 (2002), 40–52.Google Scholar

Tremaine, L. M., Wilner, K. D., Preskorn, S. H., A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin. Pharmacokinet. 32: Suppl 1 (1992), 31–6.Google Scholar

Sussman, N., Ginsberg, D. L., Bikoff, J., Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor-and imipramine-controlled trials. J. Clin. Psychiatry 62 (2001), 256–60.Google Scholar

Fava, M., Weight gain and antidepressants. J. Clin. Psychiatry 61: Suppl 11 (2000), 37–41.Google Scholar

Marcus, M. D., Wing, R. R., Guare, J., Blaire, E. H., Jawad, A., Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care 15 (1992), 253–5.Google Scholar

Rowland, D. L., Myers, L., Culver, A., Davidson, J. M., Bupropion and sexual function: a placebo-controlled prospective study on diabetic men with erectile dysfunction. J. Clin. Psychopharmacol. 17 (1997), 350–57.Google Scholar

Koro, C. E., Fedder, D. O., L'Italien, G. J., et al., Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. Br. Med. J. 325 (2002), 243–7.Google Scholar

Masand, P. S., Atypical antipsychotics and DKA: issues and controversies. Thomson Professional Postgraduate Services 2 (2002), 1–3.Google Scholar

Serynak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., Rosenheck, R., Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 159 (2002), 561–6.Google Scholar

Isojarvi, J. I., Rattya, J., Myllyla, V. V., et al., Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43 (1998), 446–51.Google Scholar

Jin, H., Meyer, J. M., Jeste, D. V., Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry 14 (2002), 59–64.Google Scholar

Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26: Suppl 1 (2003), 5–20.

O'Kane, M., Wiles, P. G., Wales, J. K., Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetes Med. 11 (1994), 105–10.Google Scholar

Breum, L., Bjerre, U., Bak, J. F., Jacobsen, S., Astrup, A., Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 44 (1995), 1570–76.Google Scholar

Mahuex, P., Ducros, F., Bourque, J., Garon, J., Chiasson, J.-L., Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int. J. Obes. 21 (1997), 97–102.Google Scholar

Loon, B. J. P., Radder, J. K., Frolich, M., Fluoxetine increases insulin action in obese nondiabetic and in obese noninsulin-dependent diabetic individuals. Int. J. Obes. 16 (1992), 79–85.Google Scholar

Norris, S. L., Lau, J., Smith, S. J., Schmid, C. H., Engelgau, M. M., Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 25 (2002), 1159–71.Google Scholar

Hamburg, B. A., Inoff, G. E., Coping with predictable crises of diabetes. Diabetes Care 6 (1983), 409–16.Google Scholar

Lane, J. D., McCaskill, C. C., Ross, S. L., Feinglos, M. N., Surwit, R. S., Relaxation training for NIDDM: predicting who may benefit. Diabetes Care 16 (1993), 1087–94.Google Scholar

Spiess, K., Sachs, G., Pietschmann, P., Prager, R., A program to reduce onset distress in unselected type I diabetic patients: effects on psychological variables and metabolic control. Eur. J. Endocrinol. 132 (1995), 580–86.Google Scholar

Pouwer, F., Snoek, F. J., Ploeg, H. M., Ader, H. J., Heine, R. J., Monitoring of psychological well-being in outpatients with diabetes: effects on mood, HbA(1c), and the patient's evaluation of the quality of diabetes care: a randomized controlled trial. Diabetes Care 24 (2001), 1929–35.Google Scholar

Surwit, R. S., Tilburg, M. A. L., Zucker, N., et al., Stress management improves long-term glycemic control in type 2 diabetes. Diabetes Care 25 (2002), 30–34.Google Scholar

Williams, J. W. Jr, Katon, W., Lin, E. H., et al., The effectiveness of depression care management on diabetes-related outcomes in older patients. Ann. Intern. Med. 140 (2004), 1015–24.Google Scholar

Robins, L. N., Helzer, J. E., Croughnan, J., Williams, J. B. W., Spitzer, R. L., NIMH Diagnostic Interview Schedule: Version III-R (Rockville, MD: National Institutes of Mental Health, 1987).

American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (Washington, DC: American Psychiatric Association, 1994).

Paykel, E. S., Methodology of live events research. Adv. Psychosom. Med. 17 (1987), 13–29.Google Scholar

Arrundell, W. A., SCL-90: Manual for a Multi-dimensional Indicator of Psychopathology (Lisse: Swets and Zeitinger, 1986).

Spielberger, C. D., Gorsuch, R. L., Luschene, R., Test Manual for the State-Trait Anxiety Inventory (Palo Alto, CA: Consulting Psychologists Press, 1970).

Keller, M. B., McCullough, J. P., Klein, D. N., et al., A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl. J. Med. 342 (2000), 1462–70.Google Scholar

Schulberg, H. C., Katon, W., Simon, G. E., Rush, J., Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch. Gen. Psychiatry 55 (1998), 1121–7.Google Scholar

Surwit, R. S., Williams, R. B., Siegler, I. C., Lane, J. D., Helms, M., Hostility, race, and glucose metabolism in nondiabetic individuals. Diabetes Care 25 (2002), 835–9.Google Scholar

Persky, V. W., Kempthorne-Rawson, J., Shekelle, R. B., Personality and risk of cancer: 20-year follow-up of the Western Electric study. Psychosom. Med. 49 (1987), 435–49.Google Scholar

Lustman, P. J., Griffith, L. S., Clouse, R. E., et al., Improvement in depression is associated with improvement in glycemic control. Diabetes 4: Suppl 1 (1995), 27A.Google Scholar

Sinha, R., Fisch, G., Teague, B., et al., Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N. Engl. J. Med. 346 (2002), 802–10.Google Scholar

McEwen, B. S., Magarinos, A. M., Reagan, L. P., Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J. Psychosom. Res. 53 (2002), 883–90.Google Scholar

Gispen, W. H., Biessels, G.-J., Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 23 (2000), 542–9.Google Scholar

Levin, B. E., Dunn-Meynell, A. A., Routh, V. H., Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. Am. J. Physiol. Endocrinol. Metab. 276 (1999), R1223–31.Google Scholar

Levin, B. E., Glucosensing neurons do more than just sense glucose. Int. J. Obes. 25: Suppl 5 (2001), 68–72.Google Scholar

Dunn-Meyell, A. A., Rawson, N. E., Levin, B. E., Distribution and phenotype of neurons containing the ATP-sensitive K+ channel. Brain Res. 814 (1998), 41–54.Google Scholar

Lustman, P. J., Freedland, K. E., Griffith, L. S., Clouse, R. E., Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23 (2000), 618–23.Google Scholar

Book contents

8 - The interrelationship of depression and diabetes

Summary

Keywords

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive